Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sana Biotechnology Inc (SANA) vs Sony Group Corp (SONY) Price & Performance

Sana Biotechnology IncTrade
Sony Group CorpTrade

Price performance (Past 24H)

Key statistics

Sana Biotechnology Inc vs Sony Group Corp — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Sony Group Corp trades at $23.7 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 122.5× Sana Biotechnology Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

SANASONY
Market Cap
$1.13B$138.43B
Sector
HealthTechnology
52-Week High
$5.92$30.26
52-Week Low
$2.68$19.32
Enterprise Value
$1.05B$136.35B
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Sony Group Corp

Sony's stock trades at $23.54, down 1.18% over 24 hours, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent earnings show mixed quarterly beats, with Q2 2026 EPS of $0.36 exceeding expectations. The company reported strong 2025 fundamentals, including $12.96T revenue and $1.14T net income, though 2026 projections indicate a net loss. Positive sentiment is driven by blockbuster film success, such as Spider-Man: Brand New Day, and a joint venture with TSMC for image sensors, highlighting growth in entertainment and technology segments.

Sony presents a favorable outlook with analyst consensus strongly bullish (68.75% buy ratings) and a potential 29.75% upside. Key opportunities include robust gaming and sensor divisions, but risks involve 2026 profit margin pressures, competitive threats, and execution challenges in new ventures. Investors should weigh solid cash flow and asset base against near-term earnings volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA

About Sony Group Corp

Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.

Read more on SONY